Financial Highlights for AEVIS VICTORIA SA – First Half 2025

AEVIS VICTORIA SA (ticker AEVS.SW) reported its first‑half 2025 results on 18 September 2025. The investment company, listed on the SIX Swiss Exchange and operating in the health‑care sector, announced a sharp turnaround in profitability and cash‑generation performance.

1. Profitability

  • Net profit attributable to shareholders: CHF 4.2 million.
    This represents a reversal from a CHF 0.8 million loss recorded in the same period of 2024.
  • The profit increase was driven largely by the integration of Spital Zofingen and Centromedico (Tessin), which expanded the company’s operational footprint and revenue base.

2. Revenue and Cash Flow

  • Revenue growth: The company reported a strong increase in revenue in the first half of 2025. While exact figures are not disclosed, the headline indicates a significant rise relative to the prior period.
  • Free cash flow: Exceeded CHF 100 million.
    This robust cash generation permits the company to reduce its debt load by more than CHF 120 million.

3. Dividend Policy

  • AEVIS VICTORIA SA announced that it intends to restart dividend payments from 2026.
    The decision follows the return to profitability and the strengthening of its cash‑flow position.

4. Market Context

  • As of 16 September 2025, the share price stood at CHF 13.20 per share.
    The 52‑week high was CHF 15.00 (29 December 2024) and the 52‑week low CHF 11.75 (2 April 2025).
    The company’s market capitalization is approximately CHF 1.12 billion.

5. Strategic Implications

  • The integration of the two hospitals expands AEVIS VICTORIA SA’s portfolio of private clinics and medical real estate, aligning with its core focus on healthcare investments.
  • The substantial free cash flow and debt reduction enhance the company’s financial flexibility, potentially supporting future acquisitions or infrastructure projects within its healthcare, lifestyle, and infrastructure sectors.

6. Conclusion

AEVIS VICTORIA SA’s first‑half 2025 results demonstrate a clear return to profitability, significant revenue growth, and a strong cash‑flow profile. The planned resumption of dividends and the ability to reduce debt position the company favorably for continued growth in the Swiss healthcare investment market.